NEW YORK (GenomeWeb News) – Hepregen and The Hamner Institutes for Health Sciences today announced a deal aimed at research to be conducted by the two partners.

Under the terms of the agreement, the two entities will carry out R&D work directed at defining the basic concepts "regarding the potential for new microliver products," and new applications and assay methods for Hepregen's existing microliver products.

The research will be led by Edward LeCluyse, associate investigator at Hamner, and Jack McGeehan, Hepregen's VP of Operations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.